Thestra Oy and Orion Corporation (Orion Pharma) have entered into a collaboration agreement to advance research in head and neck squamous cell carcinoma (HNSCC). The partnership combines Thestra’s specialized expertise in head and neck cancer biology with Orion’s strong pharmaceutical research and development capabilities.
Thestra brings unique know-how in HNSCC, including translational research approaches designed to address unmet medical needs in this complex disease area. Orion, Finland’s leading pharmaceutical company, sees the collaboration as an opportunity to strengthen its oncology research by gaining valuable scientific insights that can advance its innovation efforts.
Both companies share the ambition to advance science and improve future treatment options for patients with head and neck cancer.